Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

29.65
+0.15000.51%
Post-market: 29.650.00000.00%19:30 EDT
Volume:1.49M
Turnover:44.08M
Market Cap:5.11B
PE:13.50
High:29.78
Open:29.50
Low:29.15
Close:29.50
52wk High:30.96
52wk Low:19.69
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.95
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:3.91
PE(LYR):12.89

Loading ...

Acadia Pharmaceuticals Gets European Approval of Rett Syndrome Drug Daybu

Dow Jones
·
Yesterday

EU Approves Acadia’s DAYBU for Rett Syndrome Symptoms in Patients 5 and Older

Reuters
·
Yesterday

European Commission Approves Daybu® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

THOMSON REUTERS
·
Yesterday

Acadia Pharmaceuticals - Receives Ec Marketing Authorization for Daybu for Rett Syndrome

THOMSON REUTERS
·
Yesterday

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)

TIPRANKS
·
Aug 18

Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD)

Simply Wall St.
·
Aug 18

UBS Adjusts Price Target on ACADIA Pharmaceuticals to $49 From $45, Maintains Buy Rating

MT Newswires Live
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Aug 12

Acadia Pharmaceuticals Inc. : Needham Raises Target Price to $41 from $38

THOMSON REUTERS
·
Aug 12

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

MT Newswires Live
·
Aug 10

ACADIA Pharmaceuticals (ACAD) Gets a Buy from Citi

TIPRANKS
·
Aug 10

Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating

MT Newswires Live
·
Aug 10

Acadia Pharmaceuticals CFO Mark C. Schneyer Disposes of 25,141 Common Shares Worth $730,047.52

Reuters
·
Aug 08

ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus

Simply Wall St.
·
Aug 06

Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook

Reuters
·
Aug 06

Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook

Reuters
·
Aug 06

Acadia Pharmaceuticals is Maintained at Perform by Oppenheimer

Dow Jones
·
Aug 06

ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake Supports Improved Outlook, RBC Says

MT Newswires Live
·
Aug 06

Acadia Pharmaceuticals, Inc. : Oppenheimer Raises Target Price to $25 from $23

THOMSON REUTERS
·
Aug 05